

Maryline Bourguine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6630790/publications.pdf>

Version: 2024-02-01

44
papers

2,526
citations

236833

25
h-index

223716

46
g-index

50
all docs

50
docs citations

50
times ranked

1896
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5307-5311.	3.3	272
2	Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine, 1994, 12, 1503-1509.	1.7	162
3	Specific Vaccine Therapy in Chronic Hepatitis B: Induction of T Cell Proliferative Responses Specific for Envelope Antigens. Journal of Infectious Diseases, 1999, 180, 15-26.	1.9	162
4	Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology, 2004, 40, 874-882.	3.6	162
5	DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine, 1996, 14, 910-915.	1.7	159
6	DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12496-12501.	3.3	155
7	Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges. Journal of Hepatology, 2011, 54, 1286-1296.	1.8	117
8	Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host and Microbe, 2021, 29, 236-249.e6.	5.1	107
9	Adeno-Associated Virus-Mediated Gene Transfer Leads to Persistent Hepatitis B Virus Replication in Mice Expressing HLA-A2 and HLA-DR1 Molecules. Journal of Virology, 2013, 87, 5554-5563.	1.5	95
10	Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial"ANRS HB02 VAC-ADN. Gut, 2015, 64, 139-147.	6.1	91
11	Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine, 2006, 24, 4482-4489.	1.7	89
12	TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut, 2015, 64, 1961-1971.	6.1	83
13	Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: A possible way of circumventing "nonresponse" to HBsAg. Journal of Medical Virology, 1993, 39, 67-74.	2.5	60
14	In Vivo Induction of Specific Cytotoxic T Lymphocytes in Mice and Rhesus Macaques Immunized with DNA Vector Encoding an HIV Epitope Fused with Hepatitis B Surface Antigen. Virology, 1998, 240, 304-315.	1.1	57
15	Immunological and Antiviral Responses After Therapeutic DNA Immunization in Chronic Hepatitis B Patients Efficiently Treated by Analogues. Molecular Therapy, 2014, 22, 675-684.	3.7	51
16	DNA-based immunization against hepatitis B surface antigen (HBsAg) in normal and HBsAg-transgenic mice. Vaccine, 1997, 15, 849-852.	1.7	50
17	DNA-based immunization against the envelope proteins of the hepatitis B virus. Journal of Biotechnology, 1996, 44, 47-57.	1.9	48
18	CpG Oligodeoxynucleotides with Hepatitis B Surface Antigen (HBsAg) for Vaccination in HBsAg-Transgenic Mice. Journal of Virology, 2001, 75, 6482-6491.	1.5	44

#	ARTICLE	IF	CITATIONS
19	Up-Regulation of the ATP-Binding Cassette Transporter A1 Inhibits Hepatitis C Virus Infection. PLoS ONE, 2014, 9, e92140.	1.1	44
20	Muscle-Specific Expression of Hepatitis B Surface Antigen: No Effect on DNA-Raised Immune Responses. Virology, 1999, 260, 74-83.	1.1	41
21	Changes to the Natural Killer Cell Repertoire after Therapeutic Hepatitis B DNA Vaccination. PLoS ONE, 2010, 5, e8761.	1.1	38
22	Therapeutic vaccination against chronic hepatitis B virus infection. Journal of Clinical Virology, 2005, 34, S108-S114.	1.6	37
23	Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. Journal of Experimental Medicine, 2020, 217, .	4.2	34
24	HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection. International Immunology, 2003, 15, 1125-1136.	1.8	31
25	Hepatitis B Virus Splice-Generated Protein Induces T-Cell Responses in HLA-Transgenic Mice and Hepatitis B Virus-Infected Patients. Journal of Virology, 2007, 81, 4963-4972.	1.5	30
26	A virus-derived microRNA targets immune response genes during SARS-CoV-2 infection. EMBO Reports, 2022, 23, e54341.	2.0	30
27	Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice. EMBO Molecular Medicine, 2021, 13, e14459.	3.3	25
28	Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models. Hepatology, 2009, 50, 1380-1391.	3.6	24
29	Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?. Medical Microbiology and Immunology, 2015, 204, 121-129.	2.6	23
30	Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects. Microbes and Infection, 2006, 8, 2783-2790.	1.0	22
31	Immunization with a plasmid encoding a modified hepatitis B surface antigen carrying the receptor binding site for hepatocytes. Vaccine, 1999, 17, 1711-1718.	1.7	19
32	Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes. Research in Virology, 1993, 144, 263-267.	0.7	18
33	A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus. Molecular Therapy, 2020, 28, 1772-1782.	3.7	18
34	Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. Communications Biology, 2021, 4, 713.	2.0	17
35	An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Molecular Therapy, 2022, 30, 2984-2997.	3.7	17
36	Identification of a small molecule that primes the type I interferon response to cytosolic DNA. Scientific Reports, 2017, 7, 2561.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Is There a Neutralization Epitope in the Second Conserved Domain of HIV-1 Envelope Protein?. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 1-2.	0.5	13
38	Human Hematopoietic Reconstitution and HLA-Restricted Responses in Nonpermissive Alymphoid Mice. <i>Journal of Immunology</i> , 2014, 193, 1504-1511.	0.4	10
39	Adenoviral Delivery of Recombinant Hepatitis B Virus Expressing Foreign Antigenic Epitopes for Immunotherapy of Persistent Viral Infection. <i>Journal of Virology</i> , 2014, 88, 3004-3015.	1.5	10
40	Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model. <i>Virology</i> , 2012, 430, 10-19.	1.1	9
41	Nasal route favors the induction of CD4 + T cell responses in the liver of HBV-carrier mice immunized with a recombinant hepatitis B surface- and core-based therapeutic vaccine. <i>Antiviral Research</i> , 2018, 153, 23-32.	1.9	8
42	Plasmid Vector-Linked Maturation of Natural Killer (NK) Cells Is Coupled to Antigen-Dependent NK Cell Activation during DNA-Based Immunization in Mice. <i>Journal of Virology</i> , 2011, 85, 10201-10212.	1.5	5
43	Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes. <i>Vaccine</i> , 2015, 33, 4548-4553.	1.7	4
44	Immunogenicity of Hybrid Hepatitis B Surface Antigen Particles. <i>International Reviews of Immunology</i> , 1994, 11, 143-151.	1.5	3